Anixa Biosciences Inc (ANIX) — 10-Q Filings
All 10-Q filings from Anixa Biosciences Inc. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Anixa Narrows Losses Amidst Clinical Trial Progress
— Sep 10, 2025 Risk: high
Anixa Biosciences Inc. reported no revenue for the three and nine months ended July 31, 2025, consistent with the prior year. The company's net loss attributabl -
Anixa Narrows Q2 Loss Amid R&D Cost Cuts
— May 28, 2025 Risk: high
Anixa Biosciences Inc. reported no revenue for the three and six months ended April 30, 2025, consistent with the prior year periods. The company's net loss for -
Anixa Biosciences Q1 R&D Up Slightly, G&A Increases
— Mar 11, 2025 Risk: medium
Anixa Biosciences Inc. filed its Q1 10-Q report for the period ending January 31, 2025. The company reported research and development expenses of $1.1 million f -
Anixa Biosciences Files Q3 10-Q
— Sep 6, 2024 Risk: medium
Anixa Biosciences Inc. filed its 10-Q for the period ending July 31, 2024, reporting on its third fiscal quarter. The company, formerly ITUS Corp, is focused on -
Anixa Biosciences: R&D and G&A Expenses Decline in Q2
— Jun 4, 2024 Risk: medium
Anixa Biosciences Inc. filed its 10-Q for the period ending April 30, 2024. The company reported research and development expenses of $1.1 million for the six m -
Anixa Biosciences Inc. Files 10-Q for Period Ending January 31, 2024
— Mar 12, 2024 Risk: medium
Anixa Biosciences Inc (ANIX) filed a Quarterly Report (10-Q) with the SEC on March 12, 2024. Anixa Biosciences Inc. reported financial results for the quarter e
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX